Table of Contents
Trial overview
This article covers one authorised clinical trial of IG-TREGS, also described in the source as inducible HLA-G+ regulatory T cells or iG-Tregs.[1] The study is testing IG-TREGS as an adoptive immunotherapy, which means immune cells are given as a treatment, in adults after allogeneic hematopoietic cell transplantation from a fully matched sibling donor.[1]
The main goal is to study prevention of graft-versus-host disease (GvHD), a transplant complication where donor immune cells can attack the patient’s body.[1] The brief summary also says the study aims to evaluate safety after allo-HCT to prevent acute GvHD, often shortened to aGvHD.[1]
Who can participate
The trial is designed for adult patients undergoing hematopoietic stem cell transplantation from a fully compatible donor sibling.[1] This means the donor is a brother or sister whose tissue type matches the patient’s well enough for transplant.[1]
The source data do not list other participant groups, so the trial focus is narrow and specific to this transplant setting.[1]
What is being measured
The main outcome is to define the safety, tolerability, and maximum tolerable dose (MTD) of IG-TREGS for GvHD prevention.[1] Safety means whether the treatment causes harmful effects, while tolerability means how well patients can handle it.[1]
Researchers will measure infusion toxicity within 1 hour after the infusion and grade it using CTCAE version 4, which is a standard side-effect scoring system used in trials.[1] They will also track any other toxicities related to the infusion, including worsening of GvHD, infections, and disease relapse.[1]
Another key part of the study is dose-limiting toxicities (DLTs), which are serious side effects that help researchers decide whether a dose is too high.[1] During the dose-escalation phase, a dose is considered safe if a DLT happens in only 1 of 6 patients, or in 0 of 3 patients in a cohort.[1]
The study also follows adverse effects during the first 3 weeks after IG-TREGS infusion, and the full safety window runs until 90 days after infusion.[1] This time frame helps researchers see both early and later problems after treatment.[1]
Trial phase and status
This study is a Phase 1 trial.[1] Phase 1 studies usually focus on safety, side effects, and dose finding rather than proving that a treatment works in a large group.
The trial status is Authorised, and the planned enrollment is 26 participants.[1] The study type is interventional, which means the researchers are actively giving a treatment and measuring what happens.[1]
Key medical terms
Allogeneic transplant means the stem cells come from another person, not from the patient.[1] In this trial, the donor is a sibling who is fully compatible.[1]
Acute GvHD is a form of graft-versus-host disease that can happen soon after transplant.[1] The trial brief summary specifically mentions prevention of aGvHD.[1]
CTCAE is a standard way to grade side effects in clinical trials, so researchers can compare how serious they are.[1] Cohort means a small group of patients studied together at one dose level.[1]
Dose escalation means the dose is increased step by step in different groups to find the safest dose range.[1] This is why the study can identify the maximum tolerated dose.[1]
